Promin, a derivative of dapsone, was first tested against leprosy at the U.S. National Leprosarium at Carville, Louisiana, by Guy Faget and colleagues in 1941-1943. The results were striking: patients who had not responded to chaulmoogra treatment improved substantially on promin. Dapsone itself, as a simpler and cheaper compound, came into systematic use by 1946-1948. By the early 1950s, it was clear that dapsone was dramatically more effective than any form of chaulmoogra treatment and that it could be administered orally without the toxicity problems that had made chaulmoogra difficult to use.

 

The shift to dapsone did not immediately change the legal and social framework of leprosy treatment. The National Leprosarium at Carville continued to house patients, many of them involuntarily confined, until well after dapsone made confinement medically unjustifiable. Hawaii’s Kalaupapa settlement continued operating, in various forms, until 1969. The power of institutional momentum and social stigma maintained systems of confinement long past their medical rationale.

 

For the history of Alice Ball’s work, the transition to dapsone was the moment when the medical literature on chaulmoogra treatment began receding from active use. Papers that cited Dean’s publications on the esterification method were still in the archive, but they were increasingly historical documents rather than actively consulted clinical references. Ball’s name, partially restored by Hollmann’s 1922 paper, was mentioned in those historical documents — by researchers who specialized in the history of leprosy treatment — but was not reaching general medical education.

 

—

 

## Kalaupapa After the Treatments

 

The Kalaupapa settlement on Molokai continued operating in some form until 1969, when the last compulsory confinement order was lifted. By that point, the settlement had been a place of forced exile for 103 years, and more than eight thousand people had been sent there against their will. The majority had been Native Hawaiians.

ADVERTISEMENT
Advertisement
Share.